Jaguar Health Inc
NASDAQ:JAGX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Xpeng Inc
NYSE:XPEV
|
CN |
|
Steel & Tube Holdings Ltd
NZX:STU
|
NZ |
|
Chongqing Zaisheng Technology Co Ltd
SSE:603601
|
CN |
|
Kingsgate Consolidated Ltd
ASX:KCN
|
AU |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
SBI Life Insurance Company Ltd
NSE:SBILIFE
|
IN |
|
Etablissements Maurel et Prom SA
LSE:0F6L
|
FR |
|
Nanjing Canatal Data-Centre Environmental Tech Co Ltd
SSE:603912
|
CN |
|
T
|
Tamilnadu Petroproducts Ltd
NSE:TNPETRO
|
IN |
|
Hangzhou Shunwang Technology Co Ltd
SZSE:300113
|
CN |
|
Gentrack Group Ltd
NZX:GTK
|
NZ |
|
Remgro Ltd
OTC:RMGOF
|
ZA |
|
AU Optronics Corp
OTC:AUOTY
|
TW |
Jaguar Health Inc
Intangible Assets
Jaguar Health Inc
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Jaguar Health Inc
NASDAQ:JAGX
|
Intangible Assets
$16m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Intangible Assets
$50.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Intangible Assets
$19.1B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
30%
|
|
|
Pfizer Inc
NYSE:PFE
|
Intangible Assets
$53.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
14%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Intangible Assets
$26.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Intangible Assets
$6.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
3%
|
|
Jaguar Health Inc
Glance View
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 52 full-time employees. The company went IPO on 2015-05-13. The firm is focused on developing plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. The firm operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Its wholly owned subsidiary is Napo Pharmaceuticals, Inc.
See Also
What is Jaguar Health Inc's Intangible Assets?
Intangible Assets
16m
USD
Based on the financial report for Dec 31, 2025, Jaguar Health Inc's Intangible Assets amounts to 16m USD.
What is Jaguar Health Inc's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
-8%
Over the last year, the Intangible Assets growth was -13%. The average annual Intangible Assets growth rates for Jaguar Health Inc have been -11% over the past three years , -8% over the past five years .
